NanoSomiX and Beckman Coulter Diagnostics have partnered to develop automated blood-based immunoassays for detecting neurodegenerative disease biomarkers, aiming to enable scalable testing in clinical and research laboratories.
A multi-center study found that AI-assisted prostate biopsy review improved diagnostic consistency, reduced lab workloads, and cut turnaround times by nearly a day in UK NHS pathology labs.
A new NIH-funded study finds that elevated circular RNAs in blood may predict Alzheimer’s symptoms years in advance, outperforming current blood tests in forecasting disease progression.
Spotlight Medical’s myStage Dx AI breast cancer test has received CE marking under EU IVDR, enabling adoption in European oncology and pathology labs for recurrence risk assessment in ER+/HER2- early breast cancer patients.
Roche has developed a rapid PCR assay for the rare Ebola Bundibugyo virus, enabling research-use detection within six days to support outbreak response in Central and East Africa, according to the company.
The expanded commercialization agreement aims to increase availability of the GlycoKnow Ovarian laboratory-developed test through Aranscia's clinical workflow and technology platforms.
As autoimmune and allergy test volumes rise, labs are prioritizing workflow standardization and structured testing pathways to ensure reliable results, according to Santhosh Nair, president of immunodiagnostics at Thermo Fisher Scientific.
The assay measures lipoprotein(a) levels in molar units to improve cardiovascular risk assessment and standardization across laboratories.
The insurer will provide coverage for the multi-analyte test starting July 2026, following new data showing parity with mass spectrometry.
The NASHnext assay, powered by GENFIT's NIS4 technology, is designed to identify patients with at-risk MASH through a blood draw ordered via the Labcorp OnDemand platform.
Elevated donor-derived cell-free DNA levels are linked to higher kidney transplant failure risk, suggesting earlier detection of allograft injury before loss of kidney function.
The Cystic Fibrosis Base assay has received IVDR accreditation, ensuring high standards for detecting cystic fibrosis mutations.
The BD BACTEC FXI Culture System reduces detection time for bloodstream infections by approximately three hours compared to previous models.